Advances in siRNA and synbiotic therapies for colorectal cancer: a molecular and microbiota perspective

Area of Science:

• Oncology
• Genetics
• Microbiology

Background:

• Colorectal cancer (CRC) presents a significant global health burden with increasing incidence and mortality.
• Conventional therapies for CRC face limitations due to recurrence, toxicity, and drug resistance.
• Current treatments struggle to address both the molecular drivers and the tumor microenvironment.

Purpose of the Study:

• To review the potential of integrating siRNA-based therapeutics with synbiotics for colorectal cancer management.
• To highlight key molecular pathways and microenvironmental factors involved in CRC progression.
• To discuss delivery strategies, co-therapeutic approaches, and translational challenges for combined therapies.

Main Methods:

• Review of existing literature on siRNA therapeutics for cancer.
• Analysis of synbiotic effects on gut microbiota, immune responses, and inflammation in CRC.
• Exploration of combined RNAi and microbiome modulation strategies.
• Identification of key genetic targets and microenvironmental pathways.

Main Results:

• siRNA therapeutics offer precise gene silencing for oncogenes and chemoresistance genes but face delivery and stability challenges.
• Synbiotics modulate the gut microbiome, immune system, and inflammatory pathways relevant to CRC.
• Combining siRNA targeting with synbiotic-mediated microbiome modulation presents a complementary strategy.
• This integrated approach addresses both molecular and microenvironmental aspects of CRC.

Conclusions:

• The combination of RNAi and microbiome-based therapies holds significant promise for improving colorectal cancer management.
• Addressing both genetic alterations and the tumor microenvironment is crucial for overcoming treatment resistance.
• Further research into delivery systems and translational strategies is needed to realize the full potential of these combined approaches.